Methods for treating allan-herndon-dudley syndrome
AssigneeDexcel Pharma Technologies Ltd.
InventorsSamuel Refetoff, Roy Weiss, Khemraj Hirani
Life of this patent
Estimating the term…
Abstract
The present subject matter is directed to methods of treating Allan-Herndon-Dudley syndrome comprising administering 3,5-diiodothyropropionic acid (DITPA) to a subject in need thereof, wherein the DITPA administration reduces triiodothyronine (“T3”) serum levels to normal, increases T3 brain levels to normal, and maintains normal serum levels of thyroxine (T4) and thyroid stimulating hormone (TSH). The subject may be a child or an adult.
Claims18
A method of treating Allan-Herndon-Dudley syndrome, the method comprising administration of 3,5-diiodothyropropionic acid (DITPA) to a subject in need thereof,
- wherein administration is in a total daily dosage of about 2.5 milligrams per kilogram of body weight of the subject,
- and wherein the administration reduces triiodothyronine (T3) serum levels to normal, increases T3 brain levels to normal, increases or maintains normal serum levels of thyroxine (T4) and decreases or maintains normal thyroid stimulating hormone (TSH) serum levels.
A method of treating Allan-Herndon-Dudley syndrome comprising the following steps:
- a) administering 3,5-diiodothyropropionic acid (DITPA) daily at a first daily dosage for two weeks to a subject in need thereof;
- and
- b) administering DITPA daily at a second daily dosage for two weeks to the subject wherein the second dosage is greater than the first daily dosage,
- wherein daily administration begins three days following birth of the subject.
Dependencies are inferred from the claim text.